Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™
Elutia (NASDAQ: ELUT) has announced a new GPO agreement with Advantus Health Partners, marking its seventh GPO agreement since launching EluPro™. The agreement will expand access to EluPro™, the world's first FDA-cleared antibiotic-eluting biologic envelope for cardiac implantable electronic devices and neurostimulators.
EluPro™ combines antibiotics with a natural extracellular matrix that regenerates into patient tissue, addressing post-surgical challenges including infection, migration, and skin erosion. Dr. Kimberly Mulligan, GM and VP of Elutia's Cardiovascular Division, noted that the pilot launch has exceeded expectations, with physicians recognizing the product's unique value in preventing infections.
The partnership with Advantus Health Partners, a healthcare solutions company specializing in supply chain management and cost-savings efficiencies, will help make EluPro™ more widely available to physicians nationwide through their sustainable contracting solutions.
Elutia (NASDAQ: ELUT) ha annunciato un nuovo accordo GPO con Advantus Health Partners, segnando il suo settimo accordo GPO dalla lanciata di EluPro™. L'accordo espanderà l'accesso a EluPro™, il primo involucro biologico a rilascio di antibiotici approvato dalla FDA per dispositivi elettronici impiantabili cardiaci e neurostimolatori.
EluPro™ combina antibiotici con una matrice extracellulare naturale che si rigenera nei tessuti del paziente, affrontando le sfide post-chirurgiche come infezioni, migrazione ed erosione della pelle. La Dott.ssa Kimberly Mulligan, GM e VP della Divisione Cardiovascolare di Elutia, ha sottolineato che il lancio pilota ha superato le aspettative, con i medici che riconoscono il valore unico del prodotto nella prevenzione delle infezioni.
La partnership con Advantus Health Partners, un'azienda di soluzioni sanitarie specializzata nella gestione della catena di approvvigionamento e nell'efficienza dei risparmi sui costi, contribuirà a rendere EluPro™ più ampiamente disponibile ai medici in tutto il paese attraverso le loro soluzioni contrattuali sostenibili.
Elutia (NASDAQ: ELUT) ha anunciado un nuevo acuerdo GPO con Advantus Health Partners, marcando su séptimo acuerdo GPO desde el lanzamiento de EluPro™. El acuerdo ampliará el acceso a EluPro™, el primer sobre biológico con liberación de antibióticos aprobado por la FDA para dispositivos electrónicos implantables cardíacos y neuroestimuladores.
EluPro™ combina antibióticos con una matriz extracelular natural que se regenera en el tejido del paciente, abordando los desafíos postquirúrgicos, incluyendo infecciones, migración y erosión de la piel. La Dra. Kimberly Mulligan, GM y VP de la División Cardiovascular de Elutia, destacó que el lanzamiento piloto ha superado las expectativas, con los médicos reconociendo el valor único del producto en la prevención de infecciones.
La asociación con Advantus Health Partners, una empresa de soluciones de atención médica especializada en la gestión de la cadena de suministro y en la eficiencia de ahorro de costos, ayudará a que EluPro™ esté más disponible para los médicos en todo el país a través de sus soluciones de contratación sostenible.
Elutia (NASDAQ: ELUT)는 Advantus Health Partners와 새로운 GPO 계약을 발표하며 EluPro™ 출시 이후 일곱 번째 GPO 계약을 체결했습니다. 이 계약은 심장 이식 전자 장치 및 신경 자극기를 위한 FDA 승인 항생제 방출 생물학적 인벨로프인 EluPro™에 대한 접근을 확대할 것입니다.
EluPro™는 항생제를 환자 조직으로 재생되는 자연 세포외 기질과 결합하여 감염, 이동 및 피부 침식과 같은 수술 후 문제를 해결합니다. Kimberly Mulligan 박사, Elutia 심혈관 부서의 GM 및 VP는 파일럿 출시가 기대를 초과했으며, 의사들이 감염 예방에 있어 제품의 독특한 가치를 인식하고 있다고 언급했습니다.
공급망 관리 및 비용 절감 효율성을 전문으로 하는 의료 솔루션 회사인 Advantus Health Partners와의 파트너십은 EluPro™를 전국의 의사들에게 보다 널리 제공하는 데 도움이 될 것입니다.
Elutia (NASDAQ: ELUT) a annoncé un nouvel accord GPO avec Advantus Health Partners, marquant son septième accord GPO depuis le lancement de EluPro™. Cet accord élargira l'accès à EluPro™, le premier enveloppe biologique à libération d'antibiotiques approuvé par la FDA pour les dispositifs électroniques implantables cardiaques et les neurostimulateurs.
EluPro™ combine des antibiotiques avec une matrice extracellulaire naturelle qui se régénère dans le tissu du patient, abordant les défis post-chirurgicaux tels que les infections, la migration et l'érosion cutanée. Dr. Kimberly Mulligan, GM et VP de la Division Cardiovasculaire d'Elutia, a noté que le lancement pilote a dépassé les attentes, les médecins reconnaissant la valeur unique du produit dans la prévention des infections.
Le partenariat avec Advantus Health Partners, une entreprise de solutions de santé spécialisée dans la gestion de la chaîne d'approvisionnement et l'efficacité des économies de coûts, contribuera à rendre EluPro™ plus largement disponible pour les médecins à l'échelle nationale grâce à leurs solutions contractuelles durables.
Elutia (NASDAQ: ELUT) hat eine neue GPO-Vereinbarung mit Advantus Health Partners angekündigt, die die siebte GPO-Vereinbarung seit der Einführung von EluPro™ darstellt. Die Vereinbarung wird den Zugang zu EluPro™, dem weltweit ersten von der FDA zugelassenen antibiotikafreisetzenden biologischen Hüllmaterial für implantierbare kardiologische elektronische Geräte und Neurostimulatoren, erweitern.
EluPro™ kombiniert Antibiotika mit einer natürlichen extrazellulären Matrix, die sich in das Gewebe des Patienten regeneriert und postoperative Herausforderungen wie Infektionen, Migration und Hauterosion angeht. Dr. Kimberly Mulligan, GM und VP der kardiovaskulären Abteilung von Elutia, stellte fest, dass der Pilotstart die Erwartungen übertroffen hat, da Ärzte den einzigartigen Wert des Produkts bei der Infektionsprävention erkennen.
Die Partnerschaft mit Advantus Health Partners, einem Unternehmen für Gesundheitslösungen, das sich auf das Management von Lieferketten und Kosteneinsparungen spezialisiert hat, wird dazu beitragen, EluPro™ landesweit Ärzten durch nachhaltige Vertragslösungen zugänglicher zu machen.
- Secured seventh GPO agreement, expanding market access and distribution channels
- EluPro™ pilot launch exceeding management expectations
- First-mover advantage with unique FDA-cleared antibiotic-eluting biologic envelope
- Strong customer demand and physician recognition reported
- None.
Insights
Elutia's new GPO agreement with Advantus Health Partners represents meaningful commercial progress for their flagship EluPro product. As the seventh GPO agreement secured since launch, this deal significantly expands the distribution network for this FDA-cleared antibiotic-eluting biologic envelope.
GPO agreements are crucial market access milestones in healthcare, as they reduce procurement barriers for hospitals and health systems. Advantus specifically offers a core GPO solutions portfolio that can streamline product adoption across multiple facilities. The expanded access should accelerate EluPro's market penetration in the cardiac implantable electronic device (CIED) space.
What makes this particularly significant is EluPro's unique competitive position as the "world's first and only" FDA-cleared antibiotic-eluting biologic envelope for CIEDs and neurostimulators. This differentiation addresses critical post-surgical complications including infection, migration, and skin erosion - all of which represent significant clinical and economic burdens.
The management's statement that the pilot launch has "exceeded expectations" suggests strong initial physician adoption, though no specific metrics were provided. This systematic expansion of GPO coverage indicates the company is executing its commercialization strategy effectively, potentially laying groundwork for improved revenue generation as market access barriers continue to fall.
Seventh GPO Agreement Signed Since EluPro’s Launch
SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Advantus Health Partners (“Advantus”), to provide access of Elutia’s EluPro™ Antibiotic Eluting BioEnvelope to Advantus’ core group purchasing organizations (GPO) solutions portfolio.
“Teaming up with Advantus is another major step forward in meeting the strong customer demand for EluPro,” said Dr. Kimberly Mulligan, GM and VP of Elutia’s Cardiovascular Division. “Our pilot launch of EluPro has exceeded our expectations as physicians recognize the unique value that this antibiotic envelope brings in preventing infection for patients that use a cardiac implantable electronic device. Broadening our GPO coverage with Advantus allows us to benefit from their sustainable contracting solutions, making EluPro more widely available to physicians nationwide.”
EluPro is the world’s first and only antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration for use with cardiac implantable electronic devices (CIEDs) and neurostimulators. Combining powerful antibiotics with a natural extracellular matrix that regenerates into the patient’s own tissue, EluPro addresses critical post-surgical challenges, including infection, migration, and skin erosion, offering a transformative solution for both patients and clinicians. With the addition of Advantus, Elutia has now secured agreements with seven major national group purchasing organizations.
Advantus Health Partners is a health care solutions company that makes supply chain easier for its clients through streamlined supply chain management, organizational purchasing, operations and cost-savings efficiencies. With innovation at the forefront, and an advanced operational model, Advantus provides a portfolio of solutions to further drive value beyond contracting, all with the singular goal of reducing health care costs across the U.S. Advantus is committed to helping organizations meet business goals through its distinct solutions.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning the launch and market reception of EluPro, including the timing and anticipated success thereof. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to successfully commercialize, market and sell our newly approved EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; our ability to prevail in lawsuits and claims seeking indemnity, contribution and insurance coverage for FiberCel and other viable bone matrix product liabilities; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the November 2023 sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations that could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia’s other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
This press release was published by a CLEAR® Verified individual.
FAQ
What is the significance of Elutia's (ELUT) new GPO agreement with Advantus Health Partners?
How does Elutia's (ELUT) EluPro™ technology work in preventing CIED infections?
What makes Elutia's (ELUT) EluPro™ unique in the medical device market?
How has the market responded to Elutia's (ELUT) EluPro™ pilot launch?
